Immune dysfunction plays a pivotal role in the pathogenesis and progression of severe viral pneumonia.Both hyperactivated immune responses and immunosuppressive states may adversely affect clinical outcomes.Glucocorticoids,widely utilized as immunomodulatory agents,hold significant therapeutic value in managing this condition.Elucidating the intricate mechanisms underlying immune dysregulation in these patients,accurately assessing individualized immune profiles,and optimizing glucocorticoid regimens alongside other immunomodulatory interventions are critical to improving clini-cal success rates.This review synthesized current progress in research on immune disorders and glu-cocorticoid therapy in severe viral pneumonia,providing theoretical foundations for clinical practice to enhance patient prognosis.

With the continuous progress of tumor treatment methods in recent years, more and more emerging antitumor drugs have been approved to market and put into clinical use. In addition, some treatments that are in clinical trials such as gene therapy are also continuously making new breakthroughs. In this review, we mainly give a brief introduction to the novel antineoplastic therapies that have been clinically used in recent years, as well as the ones with remarkable efficacy and are expected to be approved for marketing.